We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App





COVID-19 Test Uses Novel High-Throughput Molecular Method for Detecting SARS-CoV-2 Infection in Saliva Samples

By LabMedica International staff writers
Posted on 30 Mar 2021
A new COVID-19 test uses a high-throughput molecular method for detecting infection by SARS-CoV-2 in specimens of saliva from individuals, allowing for fast and accurate detection of infection by the virus.

Escher Biomedical Diagnostics, LLC’s (Houston, TX, USA) Escher BT-MED COV19 Saliva Test has been accepted by FDA as a Notification under Section IV.C of the Emergency Use Authorization program. More...
The BT-MED COV19 Test system is a high-throughput molecular method for detecting infection by the SARS-CoV-2 virus in specimens of saliva from individuals suspected of COVID-19 by their healthcare provider. Escher intends to distribute the COVID-19 virus test in the US while FDA review of the EUA request is pending. At present, the BT-MED COV19 Test is for use only in CLIA-high-complexity laboratories.

The BT-MED system is composed of the BT-MED Analyzer and test kits associated with specific pathogens or panels of pathogens. The analyzer can be configured for full automated use, which minimizes the need for human technical activities, or partial automated use, which allows higher throughput. The BT-MED diagnostic device is based on in situ hybridization with fluorescent molecular probe, coupled with automated intelligent digital image processing that evaluates as to the presence or absence of the virus. There is no 'RT' and No 'PCR' because the BT-MED COV19 method uses alternate methods to amplify the signal due to the virus.

"We are pleased to introduce this important method to the detection and characterization of pathogens. The novel approach developed by Biotrack BV allows fast and accurate detection of the COVID-19 virus within infected human cells that appear in saliva," said Phil Speros of Escher. "And there are many advantages to saliva as a specimen, such as simplicity of collection, but also the ability to verify correct sample collection simply by observing the presence of the necessary small volume. These are important advantages over swab-based methods."

"After years of development our technology has come of age as a robust device that is simple to deploy and implement, even to challenging settings such as trucks and ships," said Gerard Schouten, CEO of Biotrack BV, the manufacturer of the test system. "Implementation in a clinical laboratory is easy. The fact that our system directly observes the molecular probe-lit viral nucleic acids in the infected human cells [shed in saliva] made it possible to create automated software to determine whether there is an infection or not."

Related Links:
Escher Biomedical Diagnostics, LLC


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Online QC Software
Acusera 24•7
Automated Urinalysis Solution
UN-9000
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Ultrasensitive ctDNA Assay Detects MRD in Breast, Colorectal, Renal Cancers

Minimal residual disease testing is increasingly used to guide adjuvant therapy and surveillance in solid tumors, but detecting very low levels of circulating tumor DNA remains challenging in routine practice.... Read more

Microbiology

view channel
Image: Multidrug-resistant Klebsiella pneumoniae is a growing community health concern, causing recurrent UTIs in older adults and complicating first-line antibiotic treatment (Image Credit: Adobe Stock)

Study Reveals Widespread Community Spread of Drug-Resistant Klebsiella

Multidrug-resistant Klebsiella pneumoniae is an escalating community health concern, driving recurrent urinary tract infections in older adults and complicating first-line antibiotic therapy.... Read more

Industry

view channel
Image: The proposed immunoassay uses ALZpath’s pTau217 antibody to detect Alzheimer’s disease biology in blood, supporting the growing role of blood-based biomarkers in clinical care (Photo courtesy of Shutterstock)

Agreement Supports pTau217-Based Alzheimer’s Blood Test Development

As disease-modifying therapies for Alzheimer’s disease expand, accessible diagnostics are increasingly needed to identify patients earlier. Current confirmatory methods, including PET imaging and cerebrospinal... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.